Assessing the effects of thyroid suppression on benign solitary thyroid nodules: A model for using quantitative research synthesis

Medicine

Volumn 79, Issue 1, 2000, Pages 9-26

  Csako, Gyorgy ^a   Byrd, Debbie ^a   Wesley, Robert A ^b   Sarlis, Nicholas J ^c   Skarulis, Monica C ^c   Nieman, Lynnette K ^d   Pucino, Frank ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE; THYROID HORMONE;

ARTICLE; DIAGNOSTIC PROCEDURE; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; THYROID NODULE; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME;

ADULT; ANTITHYROID AGENTS; CLINICAL TRIALS; CONSENSUS DEVELOPMENT CONFERENCES, NIH; HUMANS; RESEARCH; THYROID NODULE; THYROXINE; UNITED STATES;

EID: 0033980145     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200001000-00002     Document Type: Article

References (89)

1. Anonymous. SAS/STAT user's guide: Version 6. 4th ed. Cary, North Carolina: SAS Institute, 1990.
2. Anonymous. USP DI drug information for the health care professional. 17th ed. Rockville, Maryland: United States Pharmacopeial Convention, p 2860, 1997.
3. Astwood EB, Cassidy C, Aurbach GD. Treatment of goiter and thyroid nodules with thyroid. JAMA 174: 459-64, 1960.
4. Badillo J, Shimaoka K, Lessman EM, Marchetta FC, Sokal JE. Treatment of nontoxic goiter with sodium liothyronine. JAMA 184: 151-58, 1963.
5. Bartalena L, Pinchera A. Levothyroxine suppressive therapy: Harmful and useless or harmless and useful? J Endocrinol Invest 17: 675-77, 1994.
6. Beckett GJ, Dellet HA, Gow SM, Hussey AJ, Hayes JD, Toft AD. Raised plasma glutathione S-transferase values in hyperthyroidism and in hypothyroid patients receiving thyroxine replacement: Evidence for hepatic damage. Br Med J 291: 427-31, 1985.
7. Belfiore A, La Rosa G, Padova G, Sava L, Ippolito O, Vigneri R. The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area. Cancer 60: 3096-3102, 1987.
8. Bell GM, Sawers JSA, Forfar JC, Doig A, Toft AD. The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion. Clin Endocrinol 18: 511-16, 1983.
9. Bennedbaek FN, Nielsen LK, Hegedus L. Effect of percutaneous ethanol injection therapy versus suppressive doses of L-thyroxine on benign solitary solid cold thyroid nodules: A randomized trial. J Clin Endocrinol Metab 83: 830-35, 1998.
10. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 132: 612-28, 1990.
11. Blum M. Why do clinicians continue to debate the use of levothyroxine in the diagnosis and management of thyroid nodules? Ann Intern Med 122: 63-64, 1995.
12. Blum M, Rothschild M. Improved nonoperative diagnosis of the solitary "cold" thyroid nodule. Surgical selection based on risk factors and three months of suppression. JAMA 243: 242-45, 1980.
13. Burch HB. Evaluation and management of the solid thyroid nodule. Endocrinol Metab Clin North Am 24: 663-710, 1995.
14. Burrow GN. The thyroid: Nodules and neoplasia. In: Felig P, Baxter JD, Frohman LA, eds. Endocrinology and metabolism. 3rd ed. New York: McGraw-Hill, pp 521-53, 1995.
15. Burrow GN, Mujtaba Q, LiVolsi V, Cornog J. The incidence of carcinoma in solitary "cold" thyroid nodules. Yale J Biol Med 51: 13-17, 1978.
16. Celani MF, Mariani M, Mariani G. On the usefulness of levothyroxine suppressive therapy in the medical treatment of benign solitary, solid or predominantly solid, thyroid nodules. Acta Endocrinol 123: 603-8, 1990.
17. Cheung PSY, Lee JMH, Boey JH. Thyroxine suppressive therapy of benign solitary thyroid nodules: A prospective randomized study. World J Surg 13: 818-22, 1989.
18. Cook DJ, Guyatt GH, Laupacis A, Sackett DL, Goldberg RJ. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 108(Suppl): 227S-30S, 1995.
19. Cooper DS. Thyroxine suppression therapy for benign nodular disease. J Clin Endocrinol Metab 80: 331-34, 1995.
20. De Groot U. Thyroid neoplasia. In: De Groot LJ, Besser M, Burger HG, Jameson JL, Loriaux DL, Marshall JC, Odell WTJ, Potts JT Jr, Rubenstein AH, eds. Endocrinology. 3rd ed. Philadelphia: WB Saunders, pp 834-54, 1995.
21. De Groot LJ, Larsen PR, Hennemann G. The thyroid and its diseases. 6th ed. New York: Churchill Livingstone, p 611-96, 1996.
22. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 7: 177-88, 1986.
23. Diacianti D, Salabe GB, Olivieri A, D'erasmo E, Tomei E, Lotz-Salabe H, De Martinis C. [Efficacy of L-thyroxine (L-T4) therapy on the volume of the thyroid gland and nodules in patients with euthyroid nodular goiter]. Minerva Med 83: 745-51, 1992.
24. Dillmann WH. The thyroid. In: Bennett JC, Plum F, eds. Cecil textbook of medicine. Vol. 20. Philadelphia: WB Saunders, pp 1227-45, 1996.
25. Dong BJ. Thyroid disorders. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics: The clinical use of drugs. 6th ed. Vancouver: Applied Therapeutics, Chapter 47, pp 47.1-31, 1996.
26. Dumont JE. The action of thyrotropin on thyroid metabolism. In: Harris RS, Munson PL, Diczfalusy E, Glove J, eds. Vitamins and hormones. London: Academic Press, pp 287-412, 1971.
27. Eraker SA, Wickamasekarein R, Goldman S. Complete heart block with hyperthyroidism. JAMA 239: 1644-46, 1978.
28. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. N Engl J Med 316: 764-70, 1987.
29. Foy JL, Eastman RC, Nealon RC, Bowen PM, Pengelly ML, Drass JA, Dorworth TE, Pucino F. Automated therapeutic drug monitoring in an ambulatory care endocrine clinic. Ann Pharmacother 26: 675-78, 1992.
30. From GLA, Lawson VG. Solitary thyroid nodule: Concepts in diagnosis and treatment. In: Falk SA, ed. Thyroid disease: Endocrinology surgery, nuclear medicine, and radiotherapy. 2nd ed. Philadelphia: Lippincott-Raven, pp 411-29, 1997.
31. Galli C, Calasso F, Cant G. Suppressive therapy with levothyroxine for solitary thyroid nodules [letter]. N Engl J Med 317: 1664, 1987.
32. Gershengorn MC, McClung MR, Chu EW, Hanson TA, Weintraub BD, Robbins J. Fine-needle aspiration cytology in the preoperative diagnosis of the thyroid nodules. Ann Intern Med 87: 265-69, 1977.
33. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, Gorman CA. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med 317: 70-75, 1987.
34. Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 128: 386-94, 1998.
35. Giuffrida D, Gharib H. Controversies in the management of cold, hot, and occult thyroid nodules. Am J Med 99: 642-50, 1995.
36. Glassford GH, Fowler EF, Cole WH. The treatment of nontoxic nodular goiter with desiccated thyroid: Results and evaluation. Surgery 58: 621-26, 1965.
37. Goretzki PE, Frilling A, Roeher H-D. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 118: 48-62, 1990.
38. Greenspan FS. Thyroid nodules and thyroid cancer. West J Med 121: 359-65, 1974.
39. Greenspan FS, Rapoport B. Thyroid gland. In: Greenspan FS, ed. Basic and clinical endocrinology. 3rd ed. East Norwalk: Prentice-Hall International, pp 188-246, 1991.
40. Greer MA, Astwood EB. Treatment of simple goiter with thyroid. J Clin Endocrinol 13: 1312-31, 1953.
41. Hennessey JV, Evaul JE, Tseng YC, Burman KD, Wartofsky L. L-thyroxine dosage: A reevaluation of therapy with contemporary preparations. Ann Intern Med 105: 11-15, 1986.
42. Hermus AR, Huysmans DA. Treatment of benign nodular thyroid disease. N Engl J Med 338: 1438-47, 1998.
43. Hill AB. The environment and disease: Association or causation? Proc R Soc Med 58: 295-300, 1965.
44. Jackson SG, Wartofsky L. The thyroid nodule. In: Monaco F, Satta M, Shapiro B, Troncone L, eds. Thyroid diseases. Clinical fundamentals and therapy. Boca Raton: CRC Press, pp 253-62, 1993.
45. Kastrup EK, ed. Facts and comparisons. St. Louis, Missouri: Wolters Kluwer, p 132f, 1997.
46. La Rosa GL, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid. Ann Intern Med 122: 1-8, 1995.
47. Lamberg B-A, Hernberg CA, Hakkila R. Treatment of non-toxic goitre with thyroid preparations. Acta Endocrinol 33: 584-92, 1960.
48. Larsen PR. The thyroid. In: Wyngaarden JB, Smith LH, Bennett JC, eds. Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders, pp 1265-69, 1992.
49. Liechty RD, Stoffel PT, Zimmerman DE, Silverberg SG. Solitary thyroid nodules. Arch Surg 112: 59-61, 1977.
50. Lima N, Knobel M, Cavaliere H, Sztejnsznaijd C, Tommori E, Medeiros-Neto G. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters. Thyroid 7: 691-97, 1997.
51. Maenhaut C, Lefort A, Libert F, Parmentier M, Raspe E, Roger P, Corvilain B, Laurent E, Reuse S, Mockel J, Lamy F, Van Sande J, Dumont JE. Function, proliferation and differentiation of the dog and human thyrocyte. Horm Metab Res 23(Suppl): 41-61, 1990.
52. Mainini E, Martinelli I, Morandi G, Villa S, Stefani I, Mazzi C. Levothyroxine suppressive therapy for solitary thyroid nodule. 18: 796-99, 1995.
53. Mandel SJ, Brent G, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 119: 492-502, 1993.
54. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 328: 553-59, 1993.
55. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: A 10 year follow up report of the impact of therapy in 576 patients. Am J Med 70: 511-18, 1981.
56. McDougall IR. Thyroid disease in clinical practice. New York: Oxford University Press, p 193-206, 1992.
57. McEvoy GK, ed. AHFS 97 drug information. Bethesda, Maryland: American Society of Health-System Pharmacists, p 2476, 1997.
58. Milazzo G, La Rosa GL, Catalfamo R, Vigneri R, Belfiore A. Effect of TSH in human thyroid cells: Evidence for both mitogenic and antimitogenic effects. J Cell Biochem 49: 231-38, 1992.
59. Miller JM, Hamburger JI, Kini S. Diagnosis of thyroid nodules. Use of fine-needle aspiration and needle biopsy. JAMA 241: 481-84, 1979.
60. Morita T, Tamai H, Ohshima A, Komaki G, Matsubayashi S, Kuma K, Nakagawa T. Changes in serum thyroid hormone, thyrotropin and thyroglobulin concentrations during thyroxine therapy in patients with solitary thyroid nodules. J Clin Endocrinol Metab 69: 227-30, 1989.
61. Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Public Health 17: 1-23, 1996.
62. Moulder JE, Foster KR. Biological effects of power-frequency fields as they relate to carcinogenesis. Proc Soc Exp Biol Med 209:309-24, 1995.
63. O'Grady NP, Barie PS, Bartlett J, Bleck T, Garvey G, Jacobi J, Linden P, Maki DG, Nam M, Pasculle W, Pasquale MD, Tribett DL, Masur H. (Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America). Practice parameters for evaluating new fever in critically ill adult patients. Crit Care Med 26: 392-408, 1998.
64. Oppenheimer JH, Braverman LE, Toft A, Jackson IM, Ladenson PW. A therapeutic controversy. Thyroid hormone treatment: When and what? J Clin Endocrinol Metab 80: 2873-76, 1995.
65. Papini E, Bacci V, Panunzi C, Pacella CM, Fabbrini R, Bizzarri G, Petrucci L, Giammarco V, La Medica P, Masala M, Pitaro M, Nardi F. A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol 38: 507-13, 1993.
66. Papper S, Burrows BA, Ingbar SH, Sisson JH, Ross JF. The effects of 1-thyroxine sodium on nontoxic goiter, on myxedema and on the thyroid uptake of radioactive iodine. N Engl J Med 247: 897-99, 1952.
67. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT. Long-term L-thyroxine therapy associated with decreased bone density in premenopausal women. JAMA 259: 3137-41, 1988.
68. Persson CPA, Johansson H, Westermark K, Karlsson FA. Nodular goiter - is thyroxine medication of any value? World J Surg 6: 391-96, 1982.
69. Peter HJ, Studer H, Groscurth P. Autonomous growth, but not autonomous function in embryonic human thyroids: A clue to understanding autonomous goiter growth? J Clin Endocrinol Metab 66: 968-73, 1988.
70. Petrone LR. A primary care approach to the adult patient with nodular thyroid disease. Arch Fam Med 5: 92-100, 1996.
71. Proskey AJ, Saksena F, Towne WD. Myocardial infarction associated with thyrotoxicosis. Chest 72: 109-11, 1977.
72. Reverter JL, Lucas A, Audit L, Foz M, Sanmarti A. Suppressive therapy with levothyroxine for solitary thyroid nodules. 36: 25-28, 1992.
73. Ridgway EC. Clinical evaluation of solitary thyroid nodules. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The thyroid: A fundamental and clinical text. 7th ed. Philadelphia: Lippincott-Raven, pp 966-72, 1996.
74. Ridgway EC. Medical treatment of benign thyroid nodules: Have we defined a benefit? Ann Intern Med 128: 403-5, 1998.
75. Ross DS. Thyroid hormone suppressive therapy of sporadic nontoxic goiter. Thyroid 2: 263-69, 1992.
76. Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 82: 1167-70, 1987.
77. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE III, Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 94: 2341-50, 1996.
78. Schneeberg NG, Stahl TJ, Maldia G, Menduke H. Regression of goiter by whole thyroid or triiodothyronine. Metabolism 11: 1054-1160, 1962.
79. Shimaoka K, Sokal JE. Suppressive therapy of nontoxic goiter. Am J Med 57: 576-83, 1974.
80. Singer PA. Evaluation and management of the euthyroid nodular and diffuse goiter. In: Braverman LE, ed. Diseases of the thyroid (Contemporary endocrinology). Totowa, New Jersey: Humana Press, pp 241-63, 1997.
81. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV, Dorfman SG. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 156: 2165-72, 1996.
82. Spiliotis JD, Chalmoukis A, Androulakis JA, Vagenakis A. Thyroxine suppressive therapy of benign solitary thyroid nodules: Some problems [letter]. World J Surg 15: 304, 1991.
83. Studer H, Peter HJ, Gerber H. Natural heterogeneity of thyroid cells: The basis for understanding thyroid function and nodular goiter growth. Endocrine Rev 10: 125-35, 1989.
84. Tan GH, Gharib H. Thyroid incidentalomas: Management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126: 226-31, 1997.
85. Thomas CG, Buckwalter JA, Staab EV, Kerr CY. Evaluation of dominant thyroid masses. Ann Surg 183: 463-69, 1976.
86. Toft AD. Thyroxine therapy. N Engl J Med 331: 174-80, 1994.
87. Tunbridge WMG. The epidemiology of thyroid diseases. In: Ingbar SH, Braverman LE, eds. The thyroid. 5th ed. Philadelphia: Lippincott, pp 625-33, 1986.
88. Wartofsky L. Diseases of the thyroid. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, pp 2012-35, 1998.
89. Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with levothyroxine for solitary thyroid nodules: A double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 83: 3881-85, 1998.